Boing Boing on MSN1d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive disorder.
· 3d
FDA approves first-of-its-kind nasal spray for severe depression
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
· 3d
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental health conditions. However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine.
US Weekly on MSN9d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, MoreCelebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what they've said
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname "Special K".
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has ...
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.
2d
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback